a transcription factor of the forkhead family. A central regulator of metabolism in several cell types. May play an important role in myogenic growth and differentiation, and in the regulation of lipolysis in adipocytes by controlling the expression of adipose triglyceride lipase (ATGL), the rate-limiting lipolytic enzyme. Translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. Contains 1 fork-head domain. Note: This description may include information from UniProtKB.
Protein type: DNA binding protein; Nuclear receptor co-regulator; Transcription factor
Cellular Component: cytoplasm; nucleus; cytosol
Molecular Function: protein binding; DNA binding; protein phosphatase 2A binding; sequence-specific DNA binding; ubiquitin protein ligase binding; protein kinase binding; DNA bending activity; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; tissue development; blood vessel development; transcription, DNA-dependent; positive regulation of apoptosis; apoptosis; positive regulation of transcription, DNA-dependent; negative regulation of transcription from RNA polymerase II promoter; negative regulation of fat cell differentiation; cellular response to starvation; glucose homeostasis; negative regulation of stress-activated MAPK cascade; pattern specification process; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; positive regulation of gluconeogenesis; embryonic development; cellular response to insulin stimulus; regulation of transcription, DNA-dependent; organ development; insulin receptor signaling pathway; positive regulation of protein catabolic process; positive regulation of transcription from RNA polymerase II promoter; response to DNA damage stimulus; positive regulation of autophagy; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.